Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozanimod induction study in moderately to severely active Crohn's disease
NL-OMON55896Phase 3Completed
- Sponsor
- Shanghai Celgen Biopharma
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease comparing Ozanimod with Placebo (2 arms). Primary endpoint: Clinical remission at Week 12. Started Dec 2019; status: completed.
02
Drugs
ozanimod
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON55896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55896.